Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study

By sjmartinez • February 4, 2025

Thyssen JP, Rosmarin D, Costanzo A, Warren R, Chu CY, Chovatiya R, Ladizinski B, Hu X, Liu Y, Calimlim B, Nduaka C, Vigna N, Armstrong A. Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study. Dermatology. 2025;241(1):10-18. doi: 10.1159/000542275. Epub 2024 Oct 30. PMID: 39476813.

Tags: atopic dermatitis, Body region, Dermatology, Dupilumab, EASI, eczema, Publications, Upadacitinib

Chronic Urticaria Is Independently Associated with Atherosclerotic Cardiovascular Disease: A National Cohort Study of the MarketScan Databases

Cortes JA, Nong Y, Smart K, Aflatooni S, Palma G, Johnsen N, Ure A, Armstrong AW. Chronic Urticaria Is Independently Associated with Atherosclerotic Cardiovascular Disease:[...]

Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis

Armstrong AW, Burne R, Bin Sawad A, Lemyre A, Gauthier-Loiselle M, Guerin A, Vinson T, Milovac B, Balu S. Treatment Patterns and Economic Burden in[...]

DNA methylation profiles at hospital admission are associated with subsequent severe COVID-19 outcomes

Hsu FM, Pickering H, Bosinger SE, Eckalbar W, Maecker HT, Kim-Schulze S, Ozonoff A, Diray-Arce J, Schaenman JM, Reed EF, Pellegrini M. DNA methylation profiles[...]